Teal Health

Teal Health

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

Teal Health is a private, commercial-stage diagnostics company that has successfully brought an FDA-authorized, at-home cervical cancer screening device to market. Its core product, the Teal Wand, allows women to self-collect a sample that is then tested for high-risk HPV with accuracy equivalent to clinician-collected samples. The company operates a direct-to-consumer model with virtual clinical support, works with major insurance plans, and aims to address the significant gap in cervical cancer screening adherence in the United States. Backed by strong clinical validation and endorsements from major health organizations, Teal is positioned to capture a substantial share of the growing at-home diagnostics market.

OncologyWomen's Health

Technology Platform

The Teal Wand, an FDA-authorized device for at-home self-collection of cervicovaginal samples for primary HPV testing, integrated with a telemedicine and digital care coordination platform.

Funding History

1
Total raised:$4.2M
Seed$4.2M

Opportunities

The recent federal endorsement of self-collected HPV testing creates a massive opportunity for insurance coverage expansion.
There is a large, immediate addressable market of the ~25% of U.S.
women who are under-screened, plus a longer-term opportunity to convert a portion of the routinely screened population who prefer the convenience and privacy of at-home testing.

Risk Factors

Key risks include dependence on favorable and broad insurance reimbursement policies, potential slow market adoption due to consumer or clinician hesitancy, and the eventual entry of larger, well-funded competitors into the at-home cervical screening space.
Execution risk in logistics and customer service is also high for a young commercial-stage company.

Competitive Landscape

Teal Health is a first-mover with the only FDA-authorized device specifically for at-home cervical screening. Potential competitors include large diagnostic companies (e.g., Roche, Qiagen) that could develop their own self-collection kits for their HPV tests, and other digital health startups focusing on women's health. Traditional in-office Pap and HPV tests remain the incumbent competition.